Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

Efficacy and safety of inhaled alpha-1-antitrypsin in patients with severe alpha-1-antitrypsin deficiency and frequent exacerbations of Chronic Obstructive Pulmonary Disease.

Stolk J, Tov N, Chapman KR, Fernandez P, MacNee W, Hopkinson NS, Piitulainen E, Seersholm N, Vogelmeier CF, Bals R, McElvaney G, Stockley RA.

Eur Respir J. 2019 Aug 29. pii: 1900673. doi: 10.1183/13993003.00673-2019. [Epub ahead of print]

PMID:
31467115
2.

Oscillometry in Chronic Obstructive Lung Disease: In vitro and in vivo evaluation of the impulse oscillometry and tremoflo devices.

Lundblad LKA, Miletic R, Piitulainen E, Wollmer P.

Sci Rep. 2019 Aug 12;9(1):11618. doi: 10.1038/s41598-019-48039-x.

3.

Decline in FEV1 and hospitalized exacerbations in individuals with severe alpha-1 antitrypsin deficiency.

Hiller AM, Piitulainen E, Jehpsson L, Tanash H.

Int J Chron Obstruct Pulmon Dis. 2019 May 23;14:1075-1083. doi: 10.2147/COPD.S195847. eCollection 2019.

4.

Survival in the Swedish cohort with alpha-1-antitrypsin deficiency, up to the age of 43-45 years.

Mostafavi B, Piitulainen E, Tanash HA.

Int J Chron Obstruct Pulmon Dis. 2019 Feb 28;14:525-530. doi: 10.2147/COPD.S183205. eCollection 2019.

5.

Liver disease in adults with severe alpha-1-antitrypsin deficiency.

Tanash HA, Piitulainen E.

J Gastroenterol. 2019 Jun;54(6):541-548. doi: 10.1007/s00535-019-01548-y. Epub 2019 Jan 24.

6.

Lung function and CT lung densitometry in 37- to 39-year-old individuals with alpha-1-antitrypsin deficiency.

Mostafavi B, Diaz S, Piitulainen E, Stoel BC, Wollmer P, Tanash HA.

Int J Chron Obstruct Pulmon Dis. 2018 Nov 8;13:3689-3698. doi: 10.2147/COPD.S167497. eCollection 2018.

7.

Acoustic radiation force impulse (ARFI) elastography in a cohort of alpha-1 antitrypsin-deficient individuals and healthy volunteers.

Diaz S, Mostafavi B, Tanash HA, Piitulainen E.

Acta Radiol Open. 2018 Apr 19;7(4):2058460118768363. doi: 10.1177/2058460118768363. eCollection 2018 Apr.

8.

Deposition of inhaled nanoparticles is reduced in subjects with COPD and correlates with the extent of emphysema: proof of concept for a novel diagnostic technique.

Aaltonen HL, Jakobsson JK, Diaz S, Zackrisson S, Piitulainen E, Löndahl J, Wollmer P.

Clin Physiol Funct Imaging. 2018 Apr 10. doi: 10.1111/cpf.12517. [Epub ahead of print]

PMID:
29635884
9.

European Respiratory Society statement: diagnosis and treatment of pulmonary disease in α1-antitrypsin deficiency.

Miravitlles M, Dirksen A, Ferrarotti I, Koblizek V, Lange P, Mahadeva R, McElvaney NG, Parr D, Piitulainen E, Roche N, Stolk J, Thabut G, Turner A, Vogelmeier C, Stockley RA.

Eur Respir J. 2017 Nov 30;50(5). pii: 1700610. doi: 10.1183/13993003.00610-2017. Print 2017 Nov. Review.

10.

Survival in individuals with severe alpha 1-antitrypsin deficiency (PiZZ) in comparison to a general population with known smoking habits.

Tanash HA, Ekström M, Rönmark E, Lindberg A, Piitulainen E.

Eur Respir J. 2017 Sep 9;50(3). pii: 1700198. doi: 10.1183/13993003.00198-2017. Print 2017 Sep.

11.

Liver function in alpha-1-antitrypsin deficient individuals at 37 to 40 years of age.

Mostafavi B, Diaz S, Tanash HA, Piitulainen E.

Medicine (Baltimore). 2017 Mar;96(12):e6180. doi: 10.1097/MD.0000000000006180.

12.

Health status and lung function in the Swedish alpha 1-antitrypsin deficient cohort, identified by neonatal screening, at the age of 37-40 years.

Piitulainen E, Mostafavi B, Tanash HA.

Int J Chron Obstruct Pulmon Dis. 2017 Feb 2;12:495-500. doi: 10.2147/COPD.S120241. eCollection 2017.

13.

Long-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE).

McElvaney NG, Burdon J, Holmes M, Glanville A, Wark PA, Thompson PJ, Hernandez P, Chlumsky J, Teschler H, Ficker JH, Seersholm N, Altraja A, Mäkitaro R, Chorostowska-Wynimko J, Sanak M, Stoicescu PI, Piitulainen E, Vit O, Wencker M, Tortorici MA, Fries M, Edelman JM, Chapman KR; RAPID Extension Trial Group.

Lancet Respir Med. 2017 Jan;5(1):51-60. doi: 10.1016/S2213-2600(16)30430-1. Epub 2016 Dec 2. Erratum in: Lancet Respir Med. 2017 Feb;5(2):e13.

PMID:
27916480
14.

Cause-specific mortality in individuals with severe alpha 1-antitrypsin deficiency in comparison with the general population in Sweden.

Tanash HA, Ekström M, Wagner P, Piitulainen E.

Int J Chron Obstruct Pulmon Dis. 2016 Jul 26;11:1663-9. doi: 10.2147/COPD.S109173. eCollection 2016.

15.

Vital capacity and COPD: the Swedish CArdioPulmonary bioImage Study (SCAPIS).

Torén K, Olin AC, Lindberg A, Vikgren J, Schiöler L, Brandberg J, Johnsson Å, Engström G, Persson HL, Sköld M, Hedner J, Lindberg E, Malinovschi A, Piitulainen E, Wollmer P, Rosengren A, Janson C, Blomberg A, Bergström G.

Int J Chron Obstruct Pulmon Dis. 2016 May 2;11:927-33. doi: 10.2147/COPD.S104644. eCollection 2016.

16.

Relationship between Change in Lung Density and Long-Term Progression of Lung Function.

Stolk J, Stockley RA, Piitulainen E, Stoel BC.

Am J Respir Crit Care Med. 2015 Jul 1;192(1):114-6. doi: 10.1164/rccm.201502-0370LE. No abstract available.

PMID:
26131993
17.

Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial.

Chapman KR, Burdon JG, Piitulainen E, Sandhaus RA, Seersholm N, Stocks JM, Stoel BC, Huang L, Yao Z, Edelman JM, McElvaney NG; RAPID Trial Study Group.

Lancet. 2015 Jul 25;386(9991):360-8. doi: 10.1016/S0140-6736(15)60860-1. Epub 2015 May 27.

PMID:
26026936
18.

The Clinical Profile of Subjects Included in the Swedish National Register on Individuals with Severe Alpha 1-Antitrypsin deficiency.

Piitulainen E, Tanash HA.

COPD. 2015 May;12 Suppl 1:36-41. doi: 10.3109/15412555.2015.1021909.

PMID:
25938290
19.

The Swedish α1-Antitrypsin Screening Study: Health Status and Lung and Liver Function at Age 34.

Tanash HA, Nystedt-Düzakin M, Montero LC, Sveger T, Piitulainen E.

Ann Am Thorac Soc. 2015 Jun;12(6):807-12. doi: 10.1513/AnnalsATS.201410-452OC.

PMID:
25803183
20.

Chronic obstructive pulmonary disease is common in never-smoking patients with primary Sjögren syndrome.

Nilsson AM, Diaz S, Theander E, Hesselstrand R, Piitulainen E, Ekberg O, Wollmer P, Mandl T.

J Rheumatol. 2015 Mar;42(3):464-71. doi: 10.3899/jrheum.140370. Epub 2015 Jan 15.

PMID:
25593235
21.

Survival benefit of lung transplantation for chronic obstructive pulmonary disease in Sweden.

Tanash HA, Riise GC, Ekström MP, Hansson L, Piitulainen E.

Ann Thorac Surg. 2014 Dec;98(6):1930-5. doi: 10.1016/j.athoracsur.2014.07.030. Epub 2014 Oct 28.

PMID:
25443001
22.

Lung Function and CT Densitometry in Subjects with alpha-1-Antitrypsin Deficiency and Healthy Controls at 35 Years of Age.

Piitulainen E, Montero LC, Nystedt-Düzakin M, Stoel BC, Sveger T, Wollmer P, Tanash HA, Diaz S.

COPD. 2015 Apr;12(2):162-7. doi: 10.3109/15412555.2014.922068. Epub 2014 Oct 3.

PMID:
25280185
23.

The forced oscillation technique is a sensitive method for detecting obstructive airway disease in patients with primary Sjögren's syndrome.

Nilsson AM, Theander E, Hesselstrand R, Piitulainen E, Wollmer P, Mandl T.

Scand J Rheumatol. 2014;43(4):324-8. doi: 10.3109/03009742.2013.856466. Epub 2014 Jan 7.

PMID:
24392743
24.

Randomised controlled trial for emphysema with a selective agonist of the γ-type retinoic acid receptor.

Stolk J, Stockley RA, Stoel BC, Cooper BG, Piitulainen E, Seersholm N, Chapman KR, Burdon JG, Decramer M, Abboud RT, Mannes GP, Wouters EF, Garrett JE, Barros-Tizon JC, Russi EW, Lomas DA, MacNee WA, Rames A.

Eur Respir J. 2012 Aug;40(2):306-12. doi: 10.1183/09031936.00161911. Epub 2012 Jan 26.

25.

Frequent development of chronic obstructive pulmonary disease in primary SS--results of a longitudinal follow-up.

Mandl T, Diaz S, Ekberg O, Hesselstrand R, Piitulainen E, Wollmer P, Theander E.

Rheumatology (Oxford). 2012 May;51(5):941-6. doi: 10.1093/rheumatology/ker409. Epub 2012 Jan 17.

PMID:
22258389
26.

Survival benefit of lung transplantation in individuals with severe α1-anti-trypsin deficiency (PiZZ) and emphysema.

Tanash HA, Riise GC, Hansson L, Nilsson PM, Piitulainen E.

J Heart Lung Transplant. 2011 Dec;30(12):1342-7. doi: 10.1016/j.healun.2011.07.003. Epub 2011 Aug 6.

PMID:
21821433
27.

Performance of enhanced liver fibrosis plasma markers in asymptomatic individuals with ZZ α1-antitrypsin deficiency.

Janciauskiene S, Wallmark A, Piitulainen E, Köhnlein T, Welte T, Sveger T.

Eur J Gastroenterol Hepatol. 2011 Aug;23(8):716-20. doi: 10.1097/MEG.0b013e328347daaf.

PMID:
21617532
28.

The fibrinogen cleavage product Aα-Val360, a specific marker of neutrophil elastase activity in vivo.

Carter RI, Mumford RA, Treonze KM, Finke PE, Davies P, Si Q, Humes JL, Dirksen A, Piitulainen E, Ahmad A, Stockley RA.

Thorax. 2011 Aug;66(8):686-91. doi: 10.1136/thx.2010.154690. Epub 2011 May 26.

PMID:
21617168
29.

Alpha-1-antitrypsin deficiency and periodontitis, a pilot study.

Wallin-Bengtsson V, Piitulainen E, Hamberg K, Lindh C, Bratthall G.

Swed Dent J. 2011;35(1):33-40.

PMID:
21591598
30.

Eureka?

Stoel BC, Dirksen A, Stockley RA, Parr D, Piitulainen E, Shaker SB, Russi EW, Bakker ME, Reiber JH, Stolk J.

Radiology. 2011 May;259(2):610-1; author reply 611-2. doi: 10.1148/radiol.11102262. No abstract available.

PMID:
21502395
31.
32.

Plasma levels of TIMP-1 are higher in 34-year-old individuals with severe α1-antitrypsin deficiency.

Janciauskiene S, Subramaniyam D, Piitulainen E, Köhnlein T, Sveger T.

Thorax. 2010 Oct;65(10):937. doi: 10.1136/thx.2009.127936. Epub 2010 Sep 3. No abstract available.

PMID:
20817717
33.

CT lung densitometry in young adults with alpha-1-antitrypsin deficiency.

Bernspång E, Diaz S, Stoel B, Wollmer P, Sveger T, Piitulainen E.

Respir Med. 2011 Jan;105(1):74-9. doi: 10.1016/j.rmed.2010.06.016. Epub 2010 Aug 2.

34.

Survival in severe alpha-1-antitrypsin deficiency (PiZZ).

Tanash HA, Nilsson PM, Nilsson JA, Piitulainen E.

Respir Res. 2010 Apr 26;11:44. doi: 10.1186/1465-9921-11-44.

35.

The liver in 30-year-old individuals with alpha(1)-antitrypsin deficiency.

Bernspång E, Carlson J, Piitulainen E.

Scand J Gastroenterol. 2009;44(11):1349-55. doi: 10.3109/00365520903296669.

PMID:
19891586
36.

Exploring the optimum approach to the use of CT densitometry in a randomised placebo-controlled study of augmentation therapy in alpha 1-antitrypsin deficiency.

Parr DG, Dirksen A, Piitulainen E, Deng C, Wencker M, Stockley RA.

Respir Res. 2009 Aug 13;10:75. doi: 10.1186/1465-9921-10-75.

37.

Progression of emphysema in a 12-month hyperpolarized 3He-MRI study: lacunarity analysis provided a more sensitive measure than standard ADC analysis.

Diaz S, Casselbrant I, Piitulainen E, Magnusson P, Peterson B, Pickering E, Tuthill T, Ekberg O, Akeson P.

Acad Radiol. 2009 Jun;16(6):700-7. doi: 10.1016/j.acra.2008.12.017. Epub 2009 Apr 10.

PMID:
19362025
38.

Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiency.

Dirksen A, Piitulainen E, Parr DG, Deng C, Wencker M, Shaker SB, Stockley RA.

Eur Respir J. 2009 Jun;33(6):1345-53. doi: 10.1183/09031936.00159408. Epub 2009 Feb 5.

39.

Lung function in 30-year-old alpha-1-antitrypsin-deficient individuals.

Bernspång E, Wollmer P, Sveger T, Piitulainen E.

Respir Med. 2009 Jun;103(6):861-5. doi: 10.1016/j.rmed.2008.12.021. Epub 2009 Feb 1.

40.

Volume correction in computed tomography densitometry for follow-up studies on pulmonary emphysema.

Stoel BC, Putter H, Bakker ME, Dirksen A, Stockley RA, Piitulainen E, Russi EW, Parr D, Shaker SB, Reiber JH, Stolk J.

Proc Am Thorac Soc. 2008 Dec 15;5(9):919-24. doi: 10.1513/pats.200804-040QC.

PMID:
19056717
41.

Dark adaptation during systemic hypoxia induced by chronic respiratory insufficiency.

Thylefors J, Piitulainen E, Havelius U.

Invest Ophthalmol Vis Sci. 2009 Mar;50(3):1307-12. doi: 10.1167/iovs.08-2104. Epub 2008 Oct 20.

PMID:
18936146
42.

Clinical course and prognosis of never-smokers with severe alpha-1-antitrypsin deficiency (PiZZ).

Tanash HA, Nilsson PM, Nilsson JA, Piitulainen E.

Thorax. 2008 Dec;63(12):1091-5. doi: 10.1136/thx.2008.095497. Epub 2008 Aug 5.

PMID:
18682522
43.

Assessment of regional progression of pulmonary emphysema with CT densitometry.

Bakker ME, Putter H, Stolk J, Shaker SB, Piitulainen E, Russi EW, Stoel BC.

Chest. 2008 Nov;134(5):931-937. doi: 10.1378/chest.08-0512. Epub 2008 Jul 14.

PMID:
18625668
44.

Validity of apparent diffusion coefficient hyperpolarized 3He-MRI using MSCT and pulmonary function tests as references.

Diaz S, Casselbrant I, Piitulainen E, Magnusson P, Peterson B, Wollmer P, Leander P, Ekberg O, Akeson P.

Eur J Radiol. 2009 Aug;71(2):257-63. doi: 10.1016/j.ejrad.2008.04.013. Epub 2008 Jun 2.

PMID:
18514455
45.

Endotoxin receptor CD14 in PiZ alpha-1-antitrypsin deficiency individuals.

Sandström CS, Novoradovskaya N, Cilio CM, Piitulainen E, Sveger T, Janciauskiene S.

Respir Res. 2008 Apr 21;9:34. doi: 10.1186/1465-9921-9-34.

46.

Hyperpolarized 3He apparent diffusion coefficient MRI of the lung: reproducibility and volume dependency in healthy volunteers and patients with emphysema.

Diaz S, Casselbrant I, Piitulainen E, Pettersson G, Magnusson P, Peterson B, Wollmer P, Leander P, Ekberg O, Akeson P.

J Magn Reson Imaging. 2008 Apr;27(4):763-70. doi: 10.1002/jmri.21212.

PMID:
18344208
47.

[Alpha 1-antitrypsin and therapeutic evidence].

Piitulainen E, Löwfdahl CG.

Lakartidningen. 2008 Jan 23-29;105(4):233; author reply 233. Swedish. No abstract available.

PMID:
18306830
48.

Progression parameters for emphysema: a clinical investigation.

Stolk J, Putter H, Bakker EM, Shaker SB, Parr DG, Piitulainen E, Russi EW, Grebski E, Dirksen A, Stockley RA, Reiber JH, Stoel BC.

Respir Med. 2007 Sep;101(9):1924-30. Epub 2007 Jul 20.

49.

Respiratory symptoms and lung function in 30-year-old individuals with alpha-1-antitrypsin deficiency.

Bernspång E, Sveger T, Piitulainen E.

Respir Med. 2007 Sep;101(9):1971-6. Epub 2007 May 25.

50.

Ongoing research in Europe: Alpha One International Registry (AIR) objectives and development.

Stockley RA, Luisetti M, Miravitlles M, Piitulainen E, Fernandez P; Alpha One International Registry (AIR) group.

Eur Respir J. 2007 Mar;29(3):582-6.

Supplemental Content

Loading ...
Support Center